With the recent increase in the probability of childhood obesity, the risk of non-alcoholic fatty liver disease is increasing, so continuous ALT and AST levels are required to monitor liver disease screening, especially in obese teenagers. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.